I agree. This could easily double by the next report. As well as continued improvements in all operations, I am expecting a big positive revaluation of company assets at the next report. After all, dermatology was written down from about $90M in Dec 2022 to $20M in June 23 on the basis of poor returns, given that this operating unit has already delivered over A$13 in direct contribution over the first 4 months I expect this asset to be revalued significantly.
fair price $13.0, page-3
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.06 |
Change
0.050(1.00%) |
Mkt cap ! $426.2M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.07 | $4.99 | $57.88K | 11.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1582 | $5.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.07 | 1330 | 10 |
View Market Depth
| Last trade - 10.24am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$5.04 |
Change
0.050 ( 0.82 %) |
||||
| Open | High | Low | Volume | ||
| $5.02 | $5.06 | $5.00 | 5195 | ||
| Last updated 11.00am 04/06/2024 ? | |||||
| MYX (ASX) Chart |